Reaction
Transformation To Acute Myeloid Leukaemia reporting signals
As of the last recalculation, Transformation To Acute Myeloid Leukaemia appears in 649 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is AZACITIDINE (PRR 194.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Azacitidine | 141 | 194.4 | 195.4 |
| Blinatumomab | 55 | 184.6 | 185.6 |
| Azacitidine For | 69 | 136.0 | 136.5 |
| Hydroxyurea | 29 | 46.0 | 46.1 |
| Ifosfamide | 28 | 43.6 | 43.7 |
| Ruxolitinib | 74 | 37.3 | 37.3 |
| Darbepoetin Alfa | 56 | 36.4 | 36.4 |
| Melphalan | 24 | 35.1 | 35.1 |
| Cytarabine | 59 | 34.5 | 34.6 |
| Febuxostat Tablets 40 Mg | 10 | 32.0 | 32.0 |
| Febuxostat Tablets 80 Mg | 10 | 32.0 | 32.0 |
| Melphalan Hydrochloride | 24 | 31.8 | 31.9 |
| Posaconazole Delayed-Release | 10 | 29.6 | 29.7 |
| Venetoclax | 51 | 28.7 | 28.8 |
| Fludarabine Phosphate | 31 | 26.5 | 26.5 |
| Posaconazole | 13 | 26.2 | 26.2 |
| Nilotinib | 21 | 23.6 | 23.6 |
| Olaparib | 15 | 23.5 | 23.5 |
| Febuxostat | 10 | 19.4 | 19.4 |
| Imatinib | 10 | 18.5 | 18.5 |
| Deferasirox | 14 | 17.3 | 17.3 |
| Etoposide | 33 | 15.1 | 15.1 |
| Doxorubicin Hydrochloride | 15 | 15.1 | 15.1 |
| Doxorubicin | 36 | 13.7 | 13.7 |